FDA authorized AI tool to predict breast cancer risk
Senior medical analyst Dr. Marc Siegel discusses advances in artificial intelligence that aim to predict a person’s future breast cancer risk and the health risks of marijuana as users age.
NewYou can listen to Fox News articles now!
The U.S. Food and Drug Administration (FDA) approved two shootings every year (the only shooting of its kind) Prevent HIVGilead Sciences, the creator of the drug, announced Wednesday.
For sale under Yeztugo, the company’s injectable HIV-1 CAPSID inhibitor (Lenacapavir) reduces reduced risk Sexually acquired HIV Among adults and teenagers.
“This is a historical day of the fight against HIV,” said Daniel O’Day, chairman and CEO of California-based Gilead Sciences, in a press release.
Alzheimer’s disease can be prevented on the market with antiviral drugs
This medication only needs to be taken twice a year and has shown “significant results” Clinical research“As Gilead claims, it can change HIV prevention.
The U.S. Food and Drug Administration approved two-year shootings, Yeztugo, to prevent HIV, which the drug’s creator announced Wednesday. (Gilead Sciences via AP)
The drug is injectable under the skin and then slowly absorbs it into the body. Individuals must undergo a negative HIV-1 test before starting treatment.
Click here to get the Fox News app
In a large trial last year, not only did the drug be nearly 100% effective in preventing HIV, but it turned out that Gilead’s another drug, Truvada, such as Truvada, was proven to be better than once-daily oral medications.
The drug is injectable under the skin and then slowly absorbs it into the body. Individuals must undergo a negative HIV-1 test before starting treatment. (AP Photo/Nardes Member)
Science magazine called Lenacapavir, its “Annual Breakthrough” in 2024.
Click here to sign up for our health newsletter
The multi-stage approach used by Lenacapavir distinguishes it from other approved methods Antiviral drugs.
For sale under Yeztugo, the company’s injectable HIV-1 CAPSID inhibitor (Lenacapavir) reduces the risk of sexually obtaining HIV in adults and adolescents. (iStock)
“Although most antiviral drugs are only in one stage Virus replicationLenacapavir is designed to suppress HIV at multiple stages of its life cycle. ” Gilead’s press release said.
For more health articles, please visit www.foxnews.com/health
“Yeztugo is one of the most important scientific breakthroughs of our time and provides a very real opportunity to help end the HIV epidemic,” O’Day said in a press release.
The most common adverse reactions during clinical trials include injection site reactions, headaches and nausea, the company said.
